David Fiellin, MD
Professor of Medicine (General Medicine), of Emergency Medicine, and of Public HealthCards
About
Research
Overview
Medical Subject Headings (MeSH)
Academic Achievements & Community Involvement
Clinical Care
Overview
David Fiellin, MD, is a primary care physician specializing in addiction medicine at Yale Medicine. He received his medical education at Emory University before arriving at Yale.
Dr. Fiellin believes strongly in providing nonjudgmental and empathetic support for his patients. This is particularly important for Dr. Fiellin’s patients with substance use disorders because he wants them to know that he doesn’t define them by their diagnosis.
One of the most rewarding aspects of treating patients with addictive disorders is seeing how quickly they improve in a short amount of time, says Dr. Fiellin. “There are few things we do in primary care where we see such a rapid evolution and such positive results,” he says.
After conditions improve, Dr. Fiellin maintains relationships with his patients for years. “I have seen them often for five or ten years and we get to the point where their addictive disorder is no longer an issue and spend most of our time addressing other medical conditions or simply making sure they are up to date on their health maintenance,” he says.
In addition to treating patients with and without addiction, Dr. Fiellin conducts research on treatment of addiction in general medical settings. He is also a professor of medicine (general medicine, emergency medicine, and public health) at the Yale School of Medicine.
Clinical Specialties
Fact Sheets
Opioid Use Disorder
Learn More on Yale MedicineEmergency Medical Services
Learn More on Yale MedicineAlcohol Use Disorder
Learn More on Yale MedicineStimulant Use Disorder
Learn More on Yale Medicine
Board Certifications
Addiction Medicine
- Certification Organization
- AB of Preventive Medicine
- Original Certification Date
- 2019
Yale Medicine News
News
News
- September 23, 2024
Call for Abstracts: Yale Conference for Alcohol Research and Education 2024
- July 08, 2024Source: Yale News
Seven-day Buprenorphine Is Safe for Those With Minimal Opioid Withdrawal
- May 23, 2024
Sandy Alfano, Expert in Pharmacy and Ethics of Human Subjects Research, Retires
- April 30, 2024
Amid Opioid Overdose Crisis, Yale Program in Addiction Medicine Advises State on Drug Company Settlement Spending